NO20021695L - 5-(2-substituerte-5-heterocykylsulfonylpyrid-3-yl)-dihydro- pyrazolo[4,3-D]pyrimidin-7-oner som fosfodiesterase inhibitorer - Google Patents
5-(2-substituerte-5-heterocykylsulfonylpyrid-3-yl)-dihydro- pyrazolo[4,3-D]pyrimidin-7-oner som fosfodiesterase inhibitorerInfo
- Publication number
- NO20021695L NO20021695L NO20021695A NO20021695A NO20021695L NO 20021695 L NO20021695 L NO 20021695L NO 20021695 A NO20021695 A NO 20021695A NO 20021695 A NO20021695 A NO 20021695A NO 20021695 L NO20021695 L NO 20021695L
- Authority
- NO
- Norway
- Prior art keywords
- heterocycylsulfonylpyrid
- dihydropyrazolo
- pyrimidin
- ones
- substituted
- Prior art date
Links
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 title 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Reproductive Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Endocrinology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9924041.8A GB9924041D0 (en) | 1999-10-11 | 1999-10-11 | Pharmaceutically active compounds |
| GB0018660A GB0018660D0 (en) | 2000-07-28 | 2000-07-28 | Pharmaceutically active compounds |
| PCT/IB2000/001430 WO2001027112A1 (en) | 1999-10-11 | 2000-10-04 | 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)-dihydropyrazolo[4,3-d]pyrimidin-7-ones as phosphodiesterase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20021695D0 NO20021695D0 (no) | 2002-04-10 |
| NO20021695L true NO20021695L (no) | 2002-06-07 |
Family
ID=26244758
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20021695A NO20021695L (no) | 1999-10-11 | 2002-04-10 | 5-(2-substituerte-5-heterocykylsulfonylpyrid-3-yl)-dihydro- pyrazolo[4,3-D]pyrimidin-7-oner som fosfodiesterase inhibitorer |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US6756373B1 (es) |
| EP (1) | EP1222190A1 (es) |
| JP (1) | JP2003511452A (es) |
| KR (1) | KR20020038941A (es) |
| CN (1) | CN1378547A (es) |
| AP (1) | AP2002002455A0 (es) |
| AR (1) | AR022665A1 (es) |
| AU (1) | AU7547900A (es) |
| BG (1) | BG106568A (es) |
| BR (1) | BR0014695A (es) |
| CA (1) | CA2387353A1 (es) |
| CO (1) | CO5261539A1 (es) |
| CZ (1) | CZ20021151A3 (es) |
| DZ (1) | DZ3218A1 (es) |
| EA (1) | EA200200240A1 (es) |
| EE (1) | EE200200192A (es) |
| GT (1) | GT200000168A (es) |
| HK (1) | HK1049834A1 (es) |
| HU (1) | HUP0203438A3 (es) |
| IL (1) | IL149025A0 (es) |
| IS (1) | IS6288A (es) |
| MA (1) | MA26824A1 (es) |
| NO (1) | NO20021695L (es) |
| NZ (1) | NZ517324A (es) |
| OA (1) | OA12058A (es) |
| PA (1) | PA8504401A1 (es) |
| PE (1) | PE20010736A1 (es) |
| PL (1) | PL357522A1 (es) |
| SK (1) | SK4562002A3 (es) |
| SV (1) | SV2002000192A (es) |
| TN (1) | TNSN00198A1 (es) |
| TR (1) | TR200200954T2 (es) |
| UY (1) | UY26383A1 (es) |
| WO (1) | WO2001027112A1 (es) |
Families Citing this family (91)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7235625B2 (en) | 1999-06-29 | 2007-06-26 | Palatin Technologies, Inc. | Multiple agent therapy for sexual dysfunction |
| US6271228B1 (en) * | 2000-04-28 | 2001-08-07 | Pfizer Inc. | Blood pressure stabilization during hemodialysis |
| EP1176147A1 (en) * | 2000-07-28 | 2002-01-30 | Pfizer Limited | Process for the preparation of pyrazolo[4,3-d]pyrimidin-7-ones and intermediates thereof |
| EP1176142A1 (en) * | 2000-07-28 | 2002-01-30 | Pfizer Inc. | Process for the preparation of pyrazoles |
| US6809200B2 (en) | 2000-07-28 | 2004-10-26 | Pfizer Inc. | Process for the preparation of pyrazolo[4,3-d]pyrimidin-7-one compounds and intermediates thereof |
| US6407259B1 (en) | 2000-07-28 | 2002-06-18 | Pfizer Inc. | Process for the preparation of pyrazoles |
| GB0025782D0 (en) * | 2000-10-20 | 2000-12-06 | Pfizer Ltd | Use of inhibitors |
| GB0105893D0 (en) * | 2001-03-09 | 2001-04-25 | Pfizer Ltd | Pharmaceutically active compounds |
| US6770645B2 (en) | 2001-03-16 | 2004-08-03 | Pfizer Inc. | Pharmaceutically active compounds |
| US6784185B2 (en) | 2001-03-16 | 2004-08-31 | Pfizer Inc. | Pharmaceutically active compounds |
| GB0106661D0 (en) * | 2001-03-16 | 2001-05-09 | Pfizer Ltd | Pharmaceutically active compounds |
| JP2005511500A (ja) | 2001-08-31 | 2005-04-28 | ザ ロックフェラー ユニバーシティー | 脳におけるホスホジエステラーゼ活性およびホスホジエステラーゼ１ｂ媒介シグナル伝達の調節 |
| JP2005529927A (ja) * | 2002-05-23 | 2005-10-06 | ファイザー インコーポレイテッド | 新規な組み合わせ |
| GB0214784D0 (en) * | 2002-06-26 | 2002-08-07 | Pfizer Ltd | Novel combination |
| JP4208512B2 (ja) | 2002-07-23 | 2009-01-14 | 株式会社クラレ | ５−（２’−ピリジル）−２−ピリドン誘導体の製造方法 |
| GB0219961D0 (en) | 2002-08-28 | 2002-10-02 | Pfizer Ltd | Oxytocin inhibitors |
| US20040067985A1 (en) * | 2002-10-04 | 2004-04-08 | Fortuna Haviv | Method of inhibiting angiogenesis |
| US7323462B2 (en) | 2002-12-10 | 2008-01-29 | Pfizer Inc. | Morpholine dopamine agonists |
| DK1572173T3 (da) | 2002-12-13 | 2010-06-14 | Warner Lambert Co | Alpha-2-delta-ligand til behandling af symptomer i den nedre urinvej |
| CA2523831C (en) | 2003-04-29 | 2008-11-18 | Pfizer Inc. | 5,7-diaminopyrazolo[4,3-d]pyrimidines useful in the treatment of hypertension |
| JP2006219373A (ja) * | 2003-06-13 | 2006-08-24 | Daiichi Asubio Pharma Co Ltd | Ｐｄｅ７阻害作用を有するピリジニルピラゾロピリミジノン誘導体 |
| US7291640B2 (en) | 2003-09-22 | 2007-11-06 | Pfizer Inc. | Substituted triazole derivatives as oxytocin antagonists |
| US7572799B2 (en) | 2003-11-24 | 2009-08-11 | Pfizer Inc | Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors |
| WO2005079808A1 (en) | 2004-01-22 | 2005-09-01 | Pfizer Limited | Triazole derivatives which inhibit vasopressin antagonistic activity |
| US7649002B2 (en) | 2004-02-04 | 2010-01-19 | Pfizer Inc | (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists |
| EP1740183B8 (en) | 2004-03-05 | 2009-11-25 | Nycomed GmbH | Novel use for pde5 inhibitors |
| DK1742950T3 (da) | 2004-04-07 | 2009-03-16 | Pfizer Ltd | Pyrazolo-[4,3-D]-pyrimidiner |
| WO2006100557A1 (en) | 2005-03-21 | 2006-09-28 | Pfizer Limited | Substituted triazole derivatives as oxytocin antagonists |
| NZ564187A (en) | 2005-05-12 | 2010-03-26 | Pfizer | Anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide |
| CN101248050B (zh) | 2005-06-06 | 2013-07-17 | 武田药品工业株式会社 | 有机化合物 |
| WO2007025103A2 (en) * | 2005-08-23 | 2007-03-01 | Intra-Cellular Therapies, Inc. | Organic compounds for treating reduced dopamine receptor signalling activity |
| AR058071A1 (es) * | 2005-10-03 | 2008-01-23 | Astrazeneca Ab | Derivados de dihidropirazolo (3,4-e)(1,4)diazepina. procesos de obtencion y composiciones farmaceuticas. |
| EP1965863A2 (en) * | 2005-12-20 | 2008-09-10 | Pfizer Products Inc. | Pharmaceutical combination for the treatment of luts comprising a pde5 inhibitor and a muscarinic antagonist |
| EP2023729B1 (en) * | 2006-06-06 | 2016-05-04 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2008044767A1 (en) * | 2006-10-13 | 2008-04-17 | Takeda Pharmaceutical Company Limited | Aromatic amine derivative and use thereof |
| EP2081431B1 (en) * | 2006-11-13 | 2013-01-16 | Intra-Cellular Therapies, Inc. | Organic compounds |
| JP5837278B2 (ja) * | 2006-12-05 | 2015-12-24 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 新規使用 |
| ES2310144B1 (es) * | 2007-06-15 | 2010-01-12 | Galenicum Health, S.L. | Intermedios para la preparacion de un inhibidor de la fosfodiesterasa tipo 5. |
| CN101815520A (zh) * | 2007-10-02 | 2010-08-25 | 东亚制药株式会社 | 治疗或预防良性前列腺增生和下尿路症状的组合物和方法 |
| CA2707349C (en) * | 2007-12-06 | 2014-05-27 | Intra-Cellular Therapies, Inc. | Organic compounds useful as inhibitors of phosphodiesterase 1 |
| ES2588238T3 (es) * | 2007-12-06 | 2016-10-31 | Intra-Cellular Therapies, Inc. | Derivados de pirazolopirimidin-4,6-diona y su uso como producto farmacéutico |
| CA2740388A1 (en) * | 2008-12-06 | 2010-06-10 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2010065151A1 (en) | 2008-12-06 | 2010-06-10 | Intra-Cellular Therapies, Inc. | Organic compounds |
| AU2009322901A1 (en) | 2008-12-06 | 2010-06-10 | Intra-Cellular Therapies, Inc. | Organic compounds |
| EA201170768A1 (ru) | 2008-12-06 | 2012-05-30 | Интра-Селлулар Терапиз, Инк. | Органические соединения |
| WO2010065153A1 (en) | 2008-12-06 | 2010-06-10 | Intra-Cellular Therapies, Inc. | Organic compounds |
| MX2011005934A (es) | 2008-12-06 | 2011-12-16 | Intra Cellular Therapies Inc | Compuestos organicos. |
| JP2012513464A (ja) | 2008-12-23 | 2012-06-14 | ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク | ホスホジエステラーゼ阻害剤及びその使用 |
| WO2010098839A1 (en) | 2009-02-25 | 2010-09-02 | Intra-Cellular Therapies, Inc. | Pde 1 inhibitors for ophthalmic disorders |
| GB0903493D0 (en) | 2009-02-27 | 2009-04-08 | Vantia Ltd | New compounds |
| EP2434895A4 (en) | 2009-05-13 | 2013-08-07 | Intra Cellular Therapies Inc | ORGANIC CONNECTIONS |
| JP6166534B2 (ja) | 2009-08-05 | 2017-07-19 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 新規調節タンパク質および阻害剤 |
| US9434730B2 (en) | 2010-05-31 | 2016-09-06 | Intra-Cellular Therapies, Inc. | PDE1 inhibitor compounds |
| JP5894148B2 (ja) | 2010-05-31 | 2016-03-23 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 有機化合物 |
| TW201206937A (en) | 2010-05-31 | 2012-02-16 | Intra Cellular Therapies Inc | Organic compounds |
| US9763948B2 (en) | 2010-05-31 | 2017-09-19 | Intra-Cellular Therapies, Inc. | PDE1 inhibitory compounds and methods |
| JP6051210B2 (ja) | 2011-06-10 | 2016-12-27 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 有機化合物 |
| WO2013067309A1 (en) | 2011-11-04 | 2013-05-10 | Xion Pharmaceutical Corporation | Methods and compositions for oral administration of melanocortin receptor agonist compounds |
| WO2013109738A1 (en) | 2012-01-17 | 2013-07-25 | The Trustees Of Columbia University In The City Of New York | Novel phosphodiesterase inhibitors and uses thereof |
| WO2014127331A1 (en) | 2013-02-17 | 2014-08-21 | Intra-Cellular Therapies, Inc. | Novel uses |
| EP2968338B1 (en) | 2013-03-15 | 2019-01-09 | Intra-Cellular Therapies, Inc. | Pde1 inhibitors for use in the treatment and/or prevention of cns injuries, and pns diseases, disorders or injuries |
| ES2836129T3 (es) | 2013-03-15 | 2021-06-24 | Intra Cellular Therapies Inc | Compuestos orgánicos |
| US10899756B2 (en) | 2013-07-17 | 2021-01-26 | The Trustees Of Columbia University In The City Of New York | Phosphodiesterase inhibitors and uses thereof |
| US9849132B2 (en) | 2014-01-08 | 2017-12-26 | Intra-Cellular Therapies, Inc. | Products and pharmaceutical compositions |
| ES2732442T3 (es) | 2014-06-20 | 2019-11-22 | Intra Cellular Therapies Inc | Compuestos orgánicos |
| US10285992B2 (en) | 2014-08-07 | 2019-05-14 | Intra-Cellular Therapies, Inc. | Combinations of PDE1 inhibitors and NEP inhibitors and associated methods |
| US9546175B2 (en) | 2014-08-07 | 2017-01-17 | Intra-Cellular Therapies, Inc. | Organic compounds |
| TWI686394B (zh) | 2014-08-07 | 2020-03-01 | 美商內胞醫療公司 | 有機化合物 |
| WO2016044667A1 (en) | 2014-09-17 | 2016-03-24 | Intra-Cellular Therapies, Inc. | Compounds and methods |
| CA2969597C (en) | 2014-12-06 | 2023-10-24 | Intra-Cellular Therapies, Inc. | 1h-pyrazolo[4,3-c][1,5]naphthyridin-4(5h)-one compounds and their use as pde2 inhibitors |
| KR102557603B1 (ko) | 2014-12-06 | 2023-07-19 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 유기 화합물 |
| EP3436083A4 (en) | 2016-03-28 | 2019-11-27 | Intra-Cellular Therapies, Inc. | NOVEL COMPOSITIONS AND METHOD |
| WO2018002673A1 (en) | 2016-07-01 | 2018-01-04 | N4 Pharma Uk Limited | Novel formulations of angiotensin ii receptor antagonists |
| US20180072741A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyrimidine compounds and uses thereof |
| US20180072718A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
| MA46191A (fr) | 2016-09-09 | 2021-04-21 | Incyte Corp | Dérivés de pyrazolopyridine comme modulateurs de hpk1 et leurs utilisations pour le traitement du cancer |
| JP7134168B6 (ja) | 2016-09-12 | 2024-02-02 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 新規使用 |
| US20180228786A1 (en) | 2017-02-15 | 2018-08-16 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
| WO2019051199A1 (en) | 2017-09-08 | 2019-03-14 | Incyte Corporation | 6-CYANO-INDAZOLE COMPOUNDS AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) MODULATORS |
| US11839614B2 (en) | 2018-01-31 | 2023-12-12 | Intra-Cellular Therapies, Inc. | Methods for treating or mitigating cardiotoxicity characterized by inhibition of adenosine A2 signaling and/or adenosine A2 receptor expression |
| US10745388B2 (en) | 2018-02-20 | 2020-08-18 | Incyte Corporation | Indazole compounds and uses thereof |
| WO2019164847A1 (en) | 2018-02-20 | 2019-08-29 | Incyte Corporation | Indazole compounds and uses thereof |
| SMT202200294T1 (it) | 2018-02-20 | 2022-11-18 | Incyte Corp | Derivati di n-(fenil)-2-(fenil)pirimidina-4-carbossammide e composti correlati come inibitori di hpk1 per trattare il cancro |
| US11299473B2 (en) | 2018-04-13 | 2022-04-12 | Incyte Corporation | Benzimidazole and indole compounds and uses thereof |
| US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
| EP3856348B1 (en) | 2018-09-25 | 2024-01-03 | Incyte Corporation | Pyrazolo[4,3-d]pyrimidine compounds as alk2 and/or fgfr modulators |
| KR20220059480A (ko) | 2019-08-06 | 2022-05-10 | 인사이트 코포레이션 | 고체 형태의 hpk1 억제제 |
| JP7612672B2 (ja) | 2019-09-03 | 2025-01-14 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 新規化合物 |
| US11590209B2 (en) | 2020-01-21 | 2023-02-28 | Palatin Technologies, Inc. | Use of bremelanotide in patients with controlled hypertension |
| CN113493459B (zh) * | 2020-04-07 | 2022-12-13 | 广州白云山医药集团股份有限公司白云山制药总厂 | Pde5抑制剂化合物及其制备方法和应用 |
| US12364695B2 (en) | 2020-06-02 | 2025-07-22 | Intra-Cellular Therapies, Inc. | Methods of treating inflammatory disease |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4871843A (en) | 1983-10-18 | 1989-10-03 | Dropic-Societe Civile De Gestion De Droits De Propriete Industrielle | Cyclic benzenesulfonamides, process for their preparation and their use as active substance of pharmaceutical compositions |
| US4663326A (en) | 1985-04-04 | 1987-05-05 | Warner-Lambert Company | Pyrazolo[4,3-d]pyrimidine-5,7-(4H,6H)dione or -5-thione-7-one analogs |
| US4666908A (en) * | 1985-04-05 | 1987-05-19 | Warner-Lambert Company | 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use |
| US5075310A (en) | 1988-07-01 | 1991-12-24 | Smith Kline & French Laboratories, Ltd. | Pyrimidone derivatives as bronchodilators |
| GB8817651D0 (en) | 1988-07-25 | 1988-09-01 | Smith Kline French Lab | Chemical compounds |
| US5250534A (en) | 1990-06-20 | 1993-10-05 | Pfizer Inc. | Pyrazolopyrimidinone antianginal agents |
| GB9013750D0 (en) * | 1990-06-20 | 1990-08-08 | Pfizer Ltd | Therapeutic agents |
| GB9114760D0 (en) | 1991-07-09 | 1991-08-28 | Pfizer Ltd | Therapeutic agents |
| GB9119704D0 (en) | 1991-09-14 | 1991-10-30 | Pfizer Ltd | Therapeutic agents |
| GB9121028D0 (en) | 1991-10-03 | 1991-11-13 | Pfizer Ltd | Therapeutic agents |
| GB9126260D0 (en) | 1991-12-11 | 1992-02-12 | Pfizer Ltd | Therapeutic agents |
| GB9202238D0 (en) | 1992-02-03 | 1992-03-18 | Wellcome Found | Compounds |
| US5294612A (en) * | 1992-03-30 | 1994-03-15 | Sterling Winthrop Inc. | 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof |
| GB9213623D0 (en) | 1992-06-26 | 1992-08-12 | Pfizer Ltd | Therapeutic agents |
| US5734053A (en) | 1992-06-26 | 1998-03-31 | Pfizer Inc | Purinone antianginal agents |
| GB9218322D0 (en) | 1992-08-28 | 1992-10-14 | Pfizer Ltd | Therapeutic agents |
| GB9301192D0 (en) * | 1993-06-09 | 1993-06-09 | Trott Francis W | Flower shaped mechanised table |
| GB9315017D0 (en) * | 1993-07-20 | 1993-09-01 | Glaxo Lab Sa | Chemical compounds |
| GB9401090D0 (en) | 1994-01-21 | 1994-03-16 | Glaxo Lab Sa | Chemical compounds |
| US6143746A (en) | 1994-01-21 | 2000-11-07 | Icos Corporation | Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use |
| GB9514465D0 (en) | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Chemical compounds |
| CA2173493C (en) | 1994-08-09 | 2008-03-25 | Nobuhisa Watanabe | Fused pyridazine compounds |
| GB9423911D0 (en) * | 1994-11-26 | 1995-01-11 | Pfizer Ltd | Therapeutic agents |
| GB9423910D0 (en) * | 1994-11-26 | 1995-01-11 | Pfizer Ltd | Therapeutic agents |
| JP3713783B2 (ja) | 1995-01-20 | 2005-11-09 | 大正製薬株式会社 | １Ｈ−ピラゾロ［３，４−ｄ］ピリミジン−４−オン誘導体 |
| US5656629A (en) | 1995-03-10 | 1997-08-12 | Sanofi Winthrop, Inc. | 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof |
| NZ303886A (en) | 1995-03-10 | 1998-11-25 | Sanofi Winthrop Inc | 1-cyclopentyl (or tert butyl)-6-aryl (or heteroaryl)-pyrazolo[3,4-d]pyrimidin-4-one derivatives and medicaments |
| SI9500173B (sl) | 1995-05-19 | 2002-02-28 | Lek, | Trofazna farmacevtska oblika s konstantnim in kontroliranim sproščanjem amorfne učinkovine za enkrat dnevno aplikacijo |
| US5798375A (en) | 1995-07-03 | 1998-08-25 | Sankyo Company, Limited | Treatment of arteriosclerosis and xanthoma |
| GB9514464D0 (en) | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Medicaments |
| GB9612514D0 (en) | 1996-06-14 | 1996-08-14 | Pfizer Ltd | Novel process |
| PL336586A1 (en) | 1997-04-25 | 2000-07-03 | Pfizer | Pyrazoylpyrimidinones inhibiting the cyclic guanosine 3',5'-monophosphate phosphodiesterase of type 5 (cgmp pde5) for treating sexual disorders |
| GT199800127A (es) | 1997-08-29 | 2000-02-01 | Combinaciones terapeuticas. | |
| HUP0102543A3 (en) * | 1998-04-20 | 2002-01-28 | Pfizer | Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction and medicaments containing them |
| US6087368A (en) | 1998-06-08 | 2000-07-11 | Bristol-Myers Squibb Company | Quinazolinone inhibitors of cGMP phosphodiesterase |
| GB9823101D0 (en) * | 1998-10-23 | 1998-12-16 | Pfizer Ltd | Pharmaceutically active compounds |
| PT1123296E (pt) | 1998-10-23 | 2003-12-31 | Pfizer | Inibidores de cgmp pdes derivados da pirazolopirimidinona para tratamento da disfuncao sexual |
| CO5271697A1 (es) * | 2000-01-12 | 2003-04-30 | Pfizer Prod Inc | Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona |
| US20020013327A1 (en) * | 2000-04-18 | 2002-01-31 | Lee Andrew G. | Compositions and methods for treating female sexual dysfunction |
| US6407259B1 (en) * | 2000-07-28 | 2002-06-18 | Pfizer Inc. | Process for the preparation of pyrazoles |
| US6809200B2 (en) * | 2000-07-28 | 2004-10-26 | Pfizer Inc. | Process for the preparation of pyrazolo[4,3-d]pyrimidin-7-one compounds and intermediates thereof |
| US20020165237A1 (en) * | 2000-08-11 | 2002-11-07 | Fryburg David Albert | Treatment of the insulin resistance syndrome |
| US6548508B2 (en) * | 2000-10-20 | 2003-04-15 | Pfizer, Inc. | Use of PDE V inhibitors for improved fecundity in mammals |
| US20020091129A1 (en) * | 2000-11-20 | 2002-07-11 | Mitradev Boolell | Treatment of premature ejaculation |
| US20020173502A1 (en) * | 2001-03-09 | 2002-11-21 | Allerton Charlotte Moira Norfor | Pharmaceutically active compounds |
| US6770645B2 (en) * | 2001-03-16 | 2004-08-03 | Pfizer Inc. | Pharmaceutically active compounds |
| WO2003012095A1 (en) | 2001-07-28 | 2003-02-13 | Midwest Research Institute | Thermal tolerant exoglucanase from acidothermus cellulolyticus |
-
2000
- 2000-10-04 NZ NZ517324A patent/NZ517324A/en unknown
- 2000-10-04 AU AU75479/00A patent/AU7547900A/en not_active Abandoned
- 2000-10-04 IL IL14902500A patent/IL149025A0/xx unknown
- 2000-10-04 OA OA1200200101A patent/OA12058A/en unknown
- 2000-10-04 WO PCT/IB2000/001430 patent/WO2001027112A1/en not_active Ceased
- 2000-10-04 EP EP00964557A patent/EP1222190A1/en not_active Withdrawn
- 2000-10-04 AP APAP/P/2002/002455A patent/AP2002002455A0/en unknown
- 2000-10-04 CZ CZ20021151A patent/CZ20021151A3/cs unknown
- 2000-10-04 TR TR2002/00954T patent/TR200200954T2/xx unknown
- 2000-10-04 HK HK03101881.7A patent/HK1049834A1/zh unknown
- 2000-10-04 JP JP2001530330A patent/JP2003511452A/ja not_active Withdrawn
- 2000-10-04 CN CN00814083A patent/CN1378547A/zh active Pending
- 2000-10-04 PL PL00357522A patent/PL357522A1/xx not_active Application Discontinuation
- 2000-10-04 SK SK456-2002A patent/SK4562002A3/sk unknown
- 2000-10-04 DZ DZ003218A patent/DZ3218A1/fr active
- 2000-10-04 EA EA200200240A patent/EA200200240A1/ru unknown
- 2000-10-04 KR KR1020027004589A patent/KR20020038941A/ko not_active Ceased
- 2000-10-04 EE EEP200200192A patent/EE200200192A/xx unknown
- 2000-10-04 CA CA002387353A patent/CA2387353A1/en not_active Abandoned
- 2000-10-04 BR BR0014695-1A patent/BR0014695A/pt not_active IP Right Cessation
- 2000-10-04 HU HU0203438A patent/HUP0203438A3/hu unknown
- 2000-10-06 US US09/684,228 patent/US6756373B1/en not_active Expired - Fee Related
- 2000-10-09 UY UY26383A patent/UY26383A1/es not_active Application Discontinuation
- 2000-10-10 TN TNTNSN00198A patent/TNSN00198A1/fr unknown
- 2000-10-10 PA PA20008504401A patent/PA8504401A1/es unknown
- 2000-10-10 PE PE2000001084A patent/PE20010736A1/es not_active Application Discontinuation
- 2000-10-10 AR ARP000105332A patent/AR022665A1/es not_active Application Discontinuation
- 2000-10-10 SV SV2000000192A patent/SV2002000192A/es unknown
- 2000-10-10 CO CO00077032A patent/CO5261539A1/es not_active Application Discontinuation
- 2000-10-10 GT GT200000168A patent/GT200000168A/es unknown
-
2002
- 2002-02-26 IS IS6288A patent/IS6288A/is unknown
- 2002-04-02 BG BG106568A patent/BG106568A/bg unknown
- 2002-04-04 MA MA26585A patent/MA26824A1/fr unknown
- 2002-04-10 NO NO20021695A patent/NO20021695L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20021695D0 (no) | 5-(2-substituerte-5-heterocykylsulfonylpyrid-3-yl)-dihydro- pyrazolo[4,3-D]pyrimidin-7-oner som fosfodiesterase inhibitorer | |
| DK1235830T3 (da) | Pyrrolo[2,3-d]pyrimidin-forbindelser som proteinkinaseinhibitorer | |
| FR17C1012I2 (fr) | 2-(pyridin-2-ylamino)-pyrido [2,3-d]pyrimidin-7-ones | |
| ATE284404T1 (de) | Pyrazolo(4,3-d)pyrimidinderivate | |
| NO20021239L (no) | Pteridinoner som kinase-inhibitorer | |
| NO20043174L (no) | Pyrido[2,1-a]isokinolinderivater som DPP-IV inhibitorer | |
| NO20023828L (no) | Pyrimidin-4-on derivater som LDL-PLA2 inhibitorer | |
| DK1381363T3 (da) | Imidazo[1,2-a]pyridinderivater som mGluR5-antagonister | |
| DK1049695T3 (da) | 2-Phenyl-substituerede imidazotriazinoner som phosphodiesterase-inhibitorer | |
| DK1289985T3 (da) | Beta-carbolinderivater anvendelige som phosphodiesteraseinhibitorer | |
| DK1185529T3 (da) | Pyrazolbenzodiazepiner som CDK2-inhibitorer | |
| ZA200204510B (en) | Imidazopyridine derivatives used as phosphodiesterase VII inhibitors. | |
| AU2002221753A1 (en) | Novel 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same | |
| NO20016201D0 (no) | Tienopyrimidiner som fosfodiesteraseinhibitorer | |
| DK1534707T5 (da) | Substituerede 2,4-dihydropyrrolo[3,4-b]quinolin-9-on-derivater egnede som phosphodiesteraseinhibitorer | |
| DK1228073T3 (da) | Imidazolforbindelser som phosphodiesterase VII-inhibitorer | |
| DE50001191D1 (de) | Pyrazolo[4, 3-d]pyrimidine | |
| DK1222193T3 (da) | Imidazolderivater som phosphodiesterase VII-inhibitorer | |
| PT1326866E (pt) | 3,4-di-hidropirido[1,2-a]pirimidinas substituidas | |
| ZA200206528B (en) | Pyrimidine-4-one derivatives as LDL-PLA2 inhibitors. | |
| AU2002317850A1 (en) | 1-alkyl 0r 1-cycloalkyltriazolo(4,3-a)quinazolin-5-ones as phosphodiesterase inhibitors | |
| DK1296981T3 (da) | Substituerede pyrrolopyridinonderivater som phosphodiesteraseinhibitorer | |
| AU2002317788A1 (en) | Imidazotriazines for use as phosphodiesterase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |